India, Nov. 16 -- Key Points
* PIKTOR is Faeth's lead drug candidate, designed to inhibit multiple nodes of the PI3K/AKT/mTOR (PAM) pathway, and is being evaluated in endometrial and breast cancer.* The PAM pathway is a well-recognised target in cancer research, with potential applications across multiple tumor types.* Faeth's cash position is expected to support development through upcoming clinical milestones.
Faeth Therapeutics Inc. (FTH) has seen its stock suffer a precipitous reversal of fortune over the past two months, shedding more than 75% of its value even as the company reported encouraging mid-stage trial results for its lead investigational therapy in advanced endometrial cancer.
For comments and feedback contact: editorial@...